Skip Navigation

QJM 2008 101(12):913-914; doi:10.1093/qjmed/hcn157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bannon, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bannon, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Elements: In this month's issue

The first 10% of the full text of this article appears below.

This month's review represents yet another discussion of the use of statins. This group of drugs has for long been considered to be both efficacious and safe in the treatment and prevention of cardiovascular disease (CHD). However the possibility of interaction between statins with other drugs also used in the management of CHD has been raised. Thienopyridines because of their anti-platelet effects are frequently administered to patients in order to reduce morbidity and mortality . . . [Full Text of this Article]

Michael Bannon

Editor, QJM


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?